Anaptysbio, Inc (ANAB): Operating Income
$47.90M
Year ended 2025-12-31
$40.80M
Trailing 12 months to 2026-03-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $47.90M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$114.95M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$164.41M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | -$115.15M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$56.81M | n/m | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | -$23.88M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$107.43M | n/m | 2022-03-07, From 2019-01-01 |
| 2018-12-31 | -$66.72M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$28.78M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$3.02M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$3.32M | n/a | 2018-03-05, From 2015-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $47.90M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $23.50M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $37.30M | +20.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $67.57M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$386.00M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$159.31M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$151.17M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | -$166.90M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | -$50.17M | n/m |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗